FINDINGS OF SCIENTIFIC MISCONDUCT Release Date: February 4, 1999 P.T. Department of Health and Human Services Notice is hereby given that the Office of Research Integrity (ORI) has made a final finding of scientific misconduct in the following cases: Samar N. Roy, Ph.D., New York Blood Center: Based on a report forwarded to the Office of Research Integrity (ORI) by the New York Blood Center (NYBC) on February 26, 1998, and information obtained by ORI during its oversight review, ORI found that Dr. Roy, former assistant member, Laboratory of Membrane Biochemistry, NYBC, engaged in scientific misconduct in biomedical research supported in part by a National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), grant. Specifically, Dr. Roy intentionally falsified the claim reported in S.N. Roy, B. Kudryk, and C.M. Redman, J. Biol. Chem. 270:23761-23767 (1995) (the \'JBC 270 paper\') that he had obtained the expression of wild type and mutant fibrinogen in yeast cells. Dr. Roy falsified the claim by \'spiking\' various samples with fibrinogen obtained from mammalian sources that were submitted to other laboratories for analysis. Also, Dr. Roy intentionally falsified the data reported in Figure 2A of the JBC 270 paper by using a different exposure of the same autoradiogram that he later used in the first six lanes of Figure 2 reported in S. Roy, A. Sun, and C. Redman, J. Biol. Chem. 271:24544-24550 (1996) (the \'JBC 271 paper\'). The falsified autoradiogram in Figure 2A of the JBC 270 paper was described differently, though correctly, in Figure 2 of the JBC 271 paper. The JBC 270 paper has been retracted. Dr. Roy has accepted the ORI finding and has entered into a Voluntary Exclusion Agreement with ORI in which he has voluntarily agreed, for the three (3) year period beginning January 7, 1999: (1) to exclude himself from any contracting or subcontracting with any agency of the United States Government and from eligibility for, or involvement in nonprocurement transactions (e.g., grants and cooperative agreements) of the United States Government as defined in 45 C.F.R. Part 76 (Debarment Regulations); and (2) to exclude himself from serving in any advisory capacity to the Public Health Service (PHS), including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant. Ms. Nellie Briggs-Brown, Rush-Presbyterian-St. Luke\'s Medical Center: Based on the report of an investigation conducted by Rush-Presbyterian-St. Luke\'s Medical Center dated December 3, 1997, ORI finds that Ms. Briggs Brown, former employee, Department of Neurology, engaged in scientific misconduct in clinical research supported by two National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH) grants. Specifically, Ms. Briggs-Brown (1) falsified seven monthly screening logs for a NINDS funded study involving stroke victims (Randomized Trial of Org 10172 in Acute Ischemic Stroke Treatment) and submitted the same logs with altered dates on multiple occasions to the University of Iowa Coordinating Center; and (2) falsified several Human Investigation Committee research approval forms. None of the questioned data has been included in publications. ORI has implemented the following administrative actions for the three (3) year period beginning January 25, 1999: (1) Ms. Briggs-Brown is prohibited from serving in any advisory capacity to PHS, including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant; and (2) any institution that submits an application for PHS support for a research project on which Ms. Briggs-Brown\'s participation is proposed or which uses her in any capacity on PHS supported research, or that submits a report of PHS-funded research in which she is involved, must concurrently submit a plan for supervision of her duties to the funding agency for approval. The supervisory plan must be designed to ensure the scientific integrity of Ms. Briggs-Brown\'s research contribution. The institution also must submit a copy of the supervisory plan to ORI. Robert J. Thackeray, R.N., M.P.H., University of Pittsburgh: Based on an investigation report prepared by the University of Pittsburgh, dated June 24, 1998, and information obtained by ORI during its oversight review, ORI found that Mr. Thackeray, former program coordinator, Multi center AIDS Cohort Study (MACS), Department of Infectious Diseases and Microbiology, Graduate School of Public Health, University of Pittsburgh, engaged in scientific misconduct in research supported by the National Institutes of Health (NIH). The Pitt Men\'s Study is a component of the MACS funded by a cooperative agreement with the National Institute of Allergy and Infectious Diseases (NIAID), NIH. Specifically, Mr. Thackeray falsified and/or fabricated research data that he recorded from various tests that he was responsible for conducting on subjects enrolled in the MACS. Mr. Thackeray falsified and/or fabricated data for five subjects and reported that data on the \'Neurological Assessment Form 10\" and on the \'Instrumental Activities of Daily Living Scale\' questionnaire. The fabricated and/or falsified research data were not compiled elsewhere and were not included in any publications. Mr. Thackeray has accepted the ORI finding and has entered into a Voluntary Exclusion Agreement with ORI in which he has voluntarily agreed, for the three (3) year period beginning January 19, 1999: (1) to exclude himself from serving in any advisory capacity to the Public Health Service (PHS), including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant; and (2) that any institution that submits an application for PHS support for a research project on which his participation is proposed or which uses him in any capacity on PHS supported research, or that submits a report of PHS-funded research in which he is involved, must concurrently submit a plan for supervision of his duties to the funding agency for approval. The supervisory plan must be designed to ensure the scientific integrity of Mr. Thackeray\'s research contribution. The institution also must submit a copy of the supervisory plan to ORI INQUIRIES For further information contact: Acting Director Division of Research Investigations Office of Research Integrity 5515 Security Lane, Suite 700 Rockville, MD 20852 Telephone: (301) 443-5330
